Your Global Leader in Stem Cell Market Research
Press Releases: Press releases are provided by the issuer and may be published by BioInformant as paid content. The issuer is solely responsible for the content and claims contained within these announcements. BioInformant does not independently verify or endorse the claims made by the issuer. For questions about an individual Press Release or to submit one, write us at [email protected].
Sangamo Therapeutics (Nasdaq: SGMO) has announced it is acquiring TxCell S.A. (ENXTPA: TXCL) in a deal worth approximately €72 million. The deal is expected to be completed by the fourth quarter of 2018.
This acquisition will combine Sangamo’s unique ex vivo (outside the body) gene editing technology with TxCell’s CAR-Treg prowess, making Sangamo a new global leader in the Treg sector. [Read more…]
Aegle Therapeutics Corporation is the first extracellular vesicle (EV) company to be cleared by the FDA to enter clinical trials in humans. Headquartered in Miami, FL, the company is using allogeneic bone marrow mesenchymal stem cell (BM-MSC) derived extracellular vesicles to treat severe dermatological disorders, with a focus on burn treatments.
In May 2018, Aegle announced that the FDA cleared its first Investigational New Drug (IND) application to initiate a clinical trial in severe second degree burn patients. The company plans to launch a Phase 1/2a clinical trial of its lead product AGLE-102 in late 2018.
The open label dose escalation study will enroll patients at several sites in the U.S., evaluating the safety of extracellular vesicle therapy in burn patients. [Read more…]
Dubai, UAE, July 2018 – Hamad Alyaarbi an eight-year-old Emirati boy who suffers from the debilitating condition Sickle Cell Anemia, has had his disease cured thanks to the use of stem cells from his younger brother, Abdullah, that were stored by CryoSave Arabia. At the beginning of 2017 Hamad’s parents had made the decision to use the cord blood stem cells from his younger brother, Abdullah, for a transplant to try and save his life. The transplant took place on 23rd June 2017, and almost a year later, Hamad is now completely cured and living a happy, healthy life, disease-free. [Read more…]
San Diego, CA, USA, July 18th, 2018 – Steminent Biotherapeutics Inc. (“Steminent” or “Company”) a private, clinical-stage cell-therapy company with offices in Taiwan, San Diego and Shanghai, is pleased to announce that the United States Food and Drug Administration (“FDA”) has raised no objections to the Company’s Investigational New Drug (“IND”) application. This allows the Company to initiate its Phase II clinical trial for polyglutamine spinocerebellar ataxia (“PolyQ SCA”) to enroll patients at clinical sites in the United States. This is a key milestone for the Company’s international Stemchymal® SCA Phase II clinical trials program. [Read more…]
CELLforCURE is a French pharmaceutical group that is authorized to do CAR-T manufacturing at its bioproduction site in Les Ulis (Essonne). CELLforCURE holds two Good Manufacturing Practice (GMP) certificates that allows it to manufacture experimental and commercial cell and gene therapies.
On July 10, 2018, CELLforCURE signed an agreement to manufacture CAR-T products for Novartis. Under the terms of the agreement, CELLforCURE will produce cancer CAR-T therapies (“chimeric antigen receptor T-cells”).
Production is scheduled to begin in 2019 following transfer of Novartis’ CAR-T manufacturing technology to CELLforCURE. [Read more…]
